BioAegis Therapeutics to Present at Upcoming MedInvest Biotech & Pharma Investor Conference in NYC
September 12 2024 - 4:56PM
BioAegis Therapeutics, a pioneering biotech company at the
forefront of innovative therapies for inflammatory diseases,
announces that its Co-founder, Steve Cordovano, will present at the
upcoming MedInvest Biotech & Pharma Investor Conference in New
York City on September 18 and 19.
The presentation, “Conquering Diseases Driven by Excess
Inflammation,” will highlight BioAegis’ novel,
host-directed treatment, recombinant plasma gelsolin (rhu-pGSN).
The presentation will also discuss BioAegis’ lead indication, Acute
Respiratory Distress Syndrome (ARDS), and its recently initiated
Phase 2 global study (NCT05947955). The presentation will take
place at 10:25 a.m., Thursday, September 19.
About Plasma Gelsolin: A Multitasking
ProteinPlasma gelsolin (pGSN) holds immense promise as a
therapeutic intervention for diseases driven by inflammation due to
its multifaceted mechanism of action. Gelsolin has demonstrated the
ability to:
- Modulate the activation of the NLRP3 inflammasome and
generation of IL-1β-containing microparticles
- Facilitate uptake and killing of microbial pathogens by innate
immune cells
- Bind to and remove harmful inflammatory mediators and toxic
actin
- Regulate macrophage phenotype to modulate inflammation
About BioAegisBioAegis Therapeutics Inc. is a
NJ-based clinical-stage, private company whose mission is to
capitalize on a key component of the body’s innate immune system,
plasma gelsolin, to prevent adverse outcomes in diseases driven by
inflammation and infection.
BioAegis’ platform is built upon the recombinant form of plasma
gelsolin, a highly conserved abundant human protein in healthy
individuals. Its role is to keep inflammation localized to the site
of injury and to boost the body’s ability to clear
pathogens. Normal levels of pGSN are depleted by
diverse inflammatory conditions. Restoring gelsolin levels
with the human recombinant form,
rhu-pGSN, helps immune cells fight
infection and controls inflammation so it does not spread and cause
organ damage. Rhu-pGSN is a non-antibiotic,
host-directed, non-immunosuppressive treatment for inflammation due
to both infectious and non-infectious causes.
BioAegis has the exclusive license to broad, worldwide
intellectual property through Harvard-Brigham and Women’s Hospital.
It holds over 40 patents issued for coverage of inflammatory
disease, infection, renal failure, and neurologic disease. BioAegis
will also have US biologics exclusivity and has recently filed new
IP in areas of unmet need.
BioAegis is currently conducting a 600-patient global Phase 2
clinical trial of rhu-pGSN for moderate-to-severe ARDS. This
project has been supported in whole or in part with federal funds
from the U.S. Department of Health and Human Services;
Administration for Strategic Preparedness and Response; Biomedical
Advanced Research and Development Authority (BARDA), under contract
number 75A50123C00067.
Investor Inquiries:Steven
Cordovano203-952-6373Steve.cordovano@bioaegistx.com
Media Inquiries:Christine
Laganaclagana@bioaegistx.com
This press release contains express or implied forward-looking
statements, which are based on current expectations of management.
These statements relate to, among other things, our expectations
regarding management’s plans, objectives, and strategies. These
statements are neither promises nor guarantees but are subject to a
variety of risks and uncertainties, many of which are beyond our
control, and which could cause actual results to differ materially
from those contemplated in these forward-looking statements.
BioAegis assumes no obligation to update any forward-looking
statements appearing in this press release in the event of changing
circumstances or otherwise, and such statements are current only as
of the date they are made.